7096 — StemCell Institute Income Statement

0.000.00%

Last trade - 00:00

HealthcareSmall CapFalling Star

Annual income statement for StemCell Institute, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2019 March 31st	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,150	1,676	1,410	1,782	2,091
Cost of Revenue
Gross Profit	761	1,133	924	1,111	1,336
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	935	1,294	1,324	1,555	1,815
Operating Profit	215	382	85.9	227	276
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	215	383	91.4	213	279
Provision for Income Taxes
Net Income After Taxes	143	277	62.4	134	198
Net Income Before Extraordinary Items
Net Income	143	277	62.4	134	198
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	143	277	62.4	134	198
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	14	27.1	6.15	13.1	20.8
Dividends per Share